Background IBD is characterised by recurrent flares, but evidence on whether modifiable dietary factors influence flare risk ...

Continuing 5-ASA after escalation to advanced therapy in ulcerative colitis is associated with lower odds of clinical remission.

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Investigational rosnilimab was safe and well-tolerated; however, it did not meet the primary endpoint of the mean change from baseline in the modified Mayo Score (severity of ulcerative colitis, mMS) ...

AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis (UC) after the PD-1 agonist flunked a phase 2 study. The San Diego-based biopharma assessed rosnilimab in the midstage study ...

Please provide your email address to receive an email when new articles are posted on . Tulisokibart demonstrated correlation with clinical, endoscopic and histologic remission in UC. Clinical ...

In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ...